Is candesartan cilexetil a safe therapeutic option for early antihypertensive therapy in patients with cerebral and myocardial ischemia?
Candesartan cilexetil is a safe therapeutic option for early antihypertensive therapy in cerebral and myocardial ischemia, without causing hypotension-related adverse events.
Although the mechanisms by which angiotensin type 1 (AT1) receptor blockade affects cardiovascular morbidity and mortality are still unresolved, the present study shows that early neurohumoral inhibition has similar beneficial effects in cerebral and in myocardial ischemia. The fact that no cardiovascular or cerebrovascular event occurred as a result of hypotension is of significant clinical importance. When there is need for or no contraindication against early antihypertensive therapy, candesartan cilexetil is a safe therapeutic option according to the ACCESS results.
Schrader et al. (2003) studied this question.